Tag Archives: TAVR

tavi vs cirugia partner i

Non-Cardiac Surgery After TAVR Is Safe

Non-Cardiac Surgery After TAVR Is Safe

There are increasingly more patients who have undergone transcatheter aortic valve replacement (TAVR) and require a non-cardiac intervention, or patients with other diseases who need surgery and are diagnosed with aortic stenosis.  In addition, on many occasions, surgery must be performed as soon as possible (as in cases of cancer) or is an emergency procedure.

El Grupo MIL realizó 4 TAVIS en Paraguay

The Latin American Group of Interventionist Women Performed 4 TAVR Cases in Paraguay

The MIL-SOLACI continues to grow and keeps developing activities to foster integration and women’s participation all across Latin America.  IN this opportunity, and for the first time, the area directed by Dr. Carla Agatiello (ARG) performed 4 transcatheter aortic valve implantations (TAVR) at the National University’s Clinical Hospital of Asunción, in Paraguay.  The interventions, performed

La enfermedad vascular periférica se asocia a más eventos en el TAVI

TAVR, More Information Supports Its Use

TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized clinical trials have shown vascular complication and pacemaker implantation rates higher than SAVR in low-risk patients. This will most certainly improve as operator experience and device development advance. This is a randomized 1:1 study including 458 patients receiving

Experiencia de la cirugía

New-Generation ACURATE Neo2

Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current guidelines recommend TAVR in patients ≥75 years with intermediate risk. One of the most frequent complications of this procedure is moderate or greater aortic regurgitation (AR) after implantation. Consequently, new valves have been developed to try and reduce


TAVR: If Not Transfemoral, We Should Consider Transcaval Access

Transcatheter aortic valve replacement (TAVR) through transfemoral access has already proven its great benefits, but this access cannot be used in certain patients, and alternative accesses need to be considered for such cases. One of the most commonly used accesses is the transaxillary or transubclavian access (AX), which, however, is associated with more complications (especially

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Should Revascularization Be Performed Before TAVR in Patients with Stable Coronary Disease?

Currently, the American and European guidelines recommend coronary angioplasty in patients with severe aortic stenosis with lesions >70% (Class IIa) who will undergo transcatheter aortic valve replacement (TAVR). However, the benefit of performing a revascularization in these patients is still uncertain. This prospective multicenter study included 2025 patients divided into two groups: complete revascularization (N = 1310)

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | LYTEN Trial: V-in-V in Small Annuli

TAVR is a valid alternative to treat failed surgical bioprosthetic valves, but one of its biggest challenges is patients with a small annulus. When using self-expanding valves, supra-annular implantation is recommended. However, at present, we only have retrospective, observational studies, not large enough.  The LYTEN Trial is a randomized study in patients presenting failed bioprosthetic

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Galileo Trial: Mortality Predictors after Successful TAVR

Patients undergoing TAVR are mostly older and more fragile, with comorbidities both cardiovascular and non-cardiovascular.  Therefore, they are associated with thromboembolic and bleeding risk. This study looked mortality predictors after successful TAVR in the Galileo trial.  Mortality at 248 days was 9.2%, 5.5% being of cardiovascular cause and 3.9% non-cardiovascular.  Mortality predictors were age >85,

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

The presence of stroke after TAVR has dropped and is currently at 2%; however, it is 5 times more deadly, has negatively affected quality of life and has increased healthcare costs.  The ASTRO TAVI registry included 14 centers and 16615 TAVR procedures between 2006 y 2021. In this period, there were 484 neurological events within